drug
Furosemide Sun
Marketedupdated 3mo agoby Sun Pharmaceutical Industries Ltd
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 28 investigational indications.
indications
investigational
Hypertension
all catalysts(6)
approval · 6
Oct 7, 2022
approval
FUROSCIX (FUROSEMIDE) — FDA approval
Furosemide Sun
→
Aug 9, 2024
approval
FUROSCIX (FUROSEMIDE) — FDA approval
Furosemide Sun
→
Mar 6, 2025
approval
FUROSCIX (FUROSEMIDE) — FDA approval
Furosemide Sun
→
Oct 7, 2025
approval
LASIX ONYU (FUROSEMIDE) — FDA approval
Furosemide Sun
→
Dec 22, 2025
approval
FUROSCIX (FUROSEMIDE) — FDA approval
Furosemide Sun
→
Jan 8, 2026
approval
FUROSEMIDE — FDA approval
Furosemide Sun
→
Trials studying Furosemide Sun
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase1Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
- phase1Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
- phase1Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
- phase1Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
- phase1A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
- N/AA Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- phase1A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 3, 2034
~7.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Apr 3, 2034formulationUS 10272064
- Apr 3, 2034method-of-use (U-3462)US 11433044
- Apr 3, 2034formulationUS 12370168
- Apr 3, 2034method-of-use (U-3462)US 9884039
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that